纳武利尤单抗联合伊匹木单抗一线治疗不可切除胸膜间皮瘤的五年结局:CheckMate 743
CheckMate 743研究五年随访更新了不可切除胸膜间皮瘤患者一线纳武利尤单抗联合伊匹木单抗对比化疗的疗效与安全性,并分析生物标志物及治疗切换影响。中位随访66.8个月,双免疫联合组5年OS率为14%对比化疗6%(HR 0.74,95%CI 0.62-0.88),各组织学类型均获益;调整化疗组24%后续免疫治疗后HR为0.64(95%CI 0.53-0.78),未发现新安全性信号。
要点
- 双免疫联合一线治疗不可切除胸膜间皮瘤5年OS率14%对比化疗6%,HR 0.74。
- 各组织学类型均观察到一致的OS获益。
- 高基线M-MDSC水平与双免疫联合治疗更差OS相关(HR 1.25)。
核心结论
- 纳武利尤单抗联合伊匹木单抗一线治疗不可切除胸膜间皮瘤较化疗显示长期持久的临床获益。
- 调整化疗组后续免疫治疗后OS获益仍持续(HR 0.64,95%CI 0.53-0.78)。
- 探索性分析提示低M-MDSC亚组从双免疫联合治疗中获益更大。
- 结果进一步支持纳武利尤单抗联合伊匹木单抗作为不可切除胸膜间皮瘤一线标准治疗。
研究设计与样本
- CheckMate 743研究五年随访,评估一线纳武利尤单抗联合伊匹木单抗对比化疗的更新疗效与安全性。
- 中位随访66.8个月,分析所有随机分配患者的OS及生物标志物可评估患者(n=242)的M-MDSC水平。
- 进行化疗组后续免疫治疗切换调整分析。
主要发现
- 所有随机分配患者中,双免疫联合组5年OS率为14%,化疗组为6%(HR 0.74,95%CI 0.62-0.88)。
- 无论肿瘤组织学类型如何,均观察到相似的OS获益。
- 在生物标志物可评估且接受双免疫联合治疗的患者(n=242)中,高基线M-MDSC水平较低水平与更差OS相关(HR 1.25,95%CI 1.09-1.43)。
- 调整化疗组24%患者后续接受免疫治疗后,双免疫联合组仍显示持续OS获益(HR 0.64,95%CI 0.53-0.78)。
- 未观察到新的安全性信号。
临床怎么用
- 纳武利尤单抗联合伊匹木单抗可作为不可切除胸膜间皮瘤的一线标准治疗选择。
- 基线M-MDSC水平可能有助于识别更可能从双免疫联合治疗中获益的患者。
局限性
- M-MDSC与疗效关联为探索性分析,需进一步验证。
- 化疗组后续免疫治疗切换调整可能无法完全消除混杂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival (OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14% v 6%; hazard ratio [HR], 0.74 [95% CI, 0.62 to 0.88]); similar benefit was observed regardless of tumor histology. Of biomarker-evaluable patients treated with nivolumab plus ipilimumab (n = 242), high baseline monocytic myeloid-derived suppressor cell (M-MDSC) levels correlated with worse OS versus low M-MDSC levels (HR, 1.25 [95% CI, 1.09 to 1.43]). After adjusting for 24% of patients in the chemotherapy arm who received subsequent immunotherapy, nivolumab plus ipilimumab demonstrated continued OS benefit versus chemotherapy (HR, 0.64 [95% CI, 0.53 to 0.78]). No new safety signals were observed. These results demonstrate long-term, durable clinical benefit with nivolumab plus ipilimumab versus chemotherapy, which continued to be preserved even after treatment-switching adjustment in the chemotherapy arm. Exploratory analyses suggested greater benefit with nivolumab plus ipilimumab in the low M-MDSC subgroup. These results further support first-line nivolumab plus ipilimumab as standard of care for unresectable PM.
引用
- Scherpereel A, Baas P, Nowak AK, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. J Clin Oncol. 2026. PMID: 41734361. doi:10.1200/JCO-25-01328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。